OFIX Insider Award Adds 37% More Shares to Board Member’s Holdings

Rhea-AI Filing Summary

Orthofix Medical (NASDAQ: OFIX) filed a routine Form 4 disclosing that director Wayne Burris was granted 18,841 deferred stock units (DSUs) on 06/18/2025 at no cost as part of board compensation. The award vests in full one year after the grant date, provided continued service, and will convert to common stock within 45 days after the director leaves the board.

Following the grant, Burris’ total beneficial ownership increased to 50,539 shares, which includes 25,315 previously reported DSUs. The filing reports no share sales, cash proceeds, or changes to Orthofix’s operations or financial outlook.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BURRIS WAYNE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	18,841	$0.00	--

Holdings After Transaction: Common Stock — 50,539 shares (Direct)

Footnotes (1)

1. Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. Includes 25,315 previously reported deferred stock units.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BURRIS WAYNE

(Last) (First) (Middle)

3451 PLANO PARKWAY

(Street)

LEWISVILLE TX 75056

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orthofix Medical Inc. [ OFIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2025		A		18,841(1)	A	$0	50,539(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer.

2. Includes 25,315 previously reported deferred stock units.

	/s/ Geoffrey Gillespie, attorney-in-fact	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Orthofix shares did director Wayne Burris acquire according to the Form 4?

The filing shows an acquisition of 18,841 deferred stock units on 06/18/2025.

What is the vesting schedule for the newly granted deferred stock units?

All 18,841 DSUs vest on the first anniversary of the grant date, subject to Burris’ continued board service.

What is Wayne Burris’ total beneficial ownership after the transaction?

After the award, Burris beneficially owns 50,539 shares of Orthofix common stock.

Did the filing indicate the transaction was made under a Rule 10b5-1 trading plan?

The Rule 10b5-1 checkbox was not marked, indicating the grant was not reported as being under a 10b5-1 plan.